Sharing History Through Active Reminiscence and Photo-imagery - With MCI

Early Phase 1CompletedNCT05906667

Oregon Health and Science University23 enrolled

Overview

The SHARP-MCI study tests impact of walking and social reminiscence on cognitive function, blood pressure, and weight among healthy Black Americans and those experiencing mild cognitive impairment (MCI).

For 6 months (24 weeks), triads of healthy and MCI Black adults aged 55 and over walk 3x/week (1 mile) in Portland's historically Black neighborhoods. Triads follow GPS-mapped routes accessible via the SHARP walking application on a group tablet device. At three points along each route, GPS-triggered "Memory Markers" (historical images of local Black culture and life from1940-2010) appear on the tablet screen serving as a conversational reminisce prompt as the triad walks. At baseline and 24 weeks, cognitive function is measured via the Montreal Cognitive Assessment (MoCA), and weight and blood pressure are measured. Pre-post health surveys rate activity levels, days feeling downhearted/blue, energy level, and health status. Program evaluation surveys at month 1, 3, 6 assess mood, pace and dose of walking, prompt effectiveness, program readiness, and liklihood to recommend program to others. Focus groups at month 1, 3, 6 evaluate participants' program experience and needed changes.

Study Type

INTERVENTIONAL

Allocation

Purpose

PREVENTION

Masking

NONE

Enrollment

Conditions

Cognitive Change

Interventions

Sharing History through Active Reminiscence and Photo-imagery (SHARP)BEHAVIORAL

Participants engage in neighborhood walks and conversational reminisce three times per week over 24 weeks

Eligibility

Sex: ALLMin age: 55 YearsMax age: 95 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: * Self-identified African American * \> 55 years old * Reside or resided for \>10 years in Portland's historically Black neighborhoods (to be familiar with Memory Markers about this area) * Able to ambulate independently. Participants (n=7) with MCI will meet criteria consistent with those defined by Jak et al. 2009 and with criteria outlined by the NIA-Alzheimer's Association workgroup (2011) * Participants without cognitive impairment (n=14) will have an MMSE score \> 24 (and not meet MCI criteria). * Participants' cognitive function should allow them to get to/ from walk locations independently or with minimal assistance Exclusion Criteria: * Serious or unstable medical condition (such as, but not limited to, cardiovascular disease, pulmonary disease, or severe arthritis) where participation in the trial would, in the opinion of the investigator, pose a significant health risk to the subject. * Diagnosis of Alzheimer's disease, vascular dementia, Parkinson's disease, or other dementing illness.

Locations (1)

Oregon Health & Science University

Portland, Oregon, United States

Outcomes

Primary Outcomes

Cognitive function

Pre/post Montreal Cognitive Assessment

Time frame: 24 weeks

Secondary Outcomes

Blood pressure

pre/post blood pressure reading

Time frame: 24 weeks

Weight

pre/post weight measurement

Time frame: 24 weeks

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.